13F Holdings
中文EN

NBIX NEUROCRINE BIOSCIENCES INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 914475 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY38.0%
TTM net income YoY64.1%
TTM EPS YoY60.9%
Revenue 3-yr CAGR27.5%
Net income 3-yr CAGR54.4%

Margins

Gross margin97.8%
Operating margin24.0%
Net margin19.0%
FCF margin28.1%
EBITDA margin24.8%

Returns

ROE20.4%
ROA14.2%
ROIC (approx.)22.7%
Asset turnover0.75x

Leverage & solvency

Liabilities / assets31.1%
Debt / equity0.00x
Current ratio2.04x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.52x
Accruals ratio-7.3%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2.86B$2.36B$1.89B$1.49B$1.13B
Cost of revenue$52.10M$34.00M$39.70M$23.20M$14.30M
Gross profit$2.81B$2.32B$1.85B$1.47B$1.12B
R&D expense$1.02B$731.10M$565.00M$463.80M$328.10M
SG&A expense$1.16B$1.01B$887.60M$752.70M$583.30M
Operating income$619.10M$570.50M$250.90M$249.00M$102.50M
Interest expense——$4.60M$7.10M$25.80M
Pretax income$705.40M$486.00M$332.10M$213.90M$101.40M
Income tax$226.80M$144.70M$82.40M$59.40M$11.80M
Net income$478.60M$341.30M$249.70M$154.50M$89.60M
EBITDA$645.10M$594.00M$268.70M$264.10M$113.40M
EPS (basic)4.813.402.561.610.95
EPS (diluted)4.673.292.471.560.92
Weighted avg. shares (diluted)102.50M103.70M101.00M98.90M97.90M
Balance sheet
Cash & equivalents$713.00M$241.00M$259.10M$270.70M$344.00M
Short-term investments$767.40M$843.10M$780.50M$726.40M$370.50M
Receivables$686.80M$479.10M$439.30M$350.00M$185.50M
Inventory$69.00M$57.40M$38.30M$35.10M$30.50M
Current assets$2.52B$1.72B$1.61B$1.45B$972.80M
PP&E, net$89.80M$82.60M$70.80M$58.60M$58.60M
Goodwill$6.10M$5.70M$5.80M$5.40M$0
Intangibles$4.70M$36.50M$35.50M$37.20M$0
Total assets$4.63B$3.72B$3.25B$2.37B$2.07B
Current liabilities$743.40M$507.70M$654.80M$537.70M$245.80M
Total liabilities$1.38B$1.13B$1.02B$660.90M$698.50M
Shareholders' equity$3.25B$2.59B$2.23B$1.71B$1.37B
Shares outstanding100.10M99.40M98.70M96.50M94.90M
Cash flow statement
Operating cash flow$782.70M$595.40M$389.90M$339.40M$256.50M
Capital expenditure$34.00M$38.20M$28.30M$16.50M$23.40M
Free cash flow$748.70M$557.20M$361.60M$322.90M$233.10M
Investing cash flow-$264.40M-$126.80M-$467.10M-$177.10M-$130.20M
Financing cash flow-$38.30M-$486.70M$65.30M-$234.30M$27.40M
Depreciation & amortization$26.00M$23.50M$17.80M$15.10M$10.90M
Stock-based compensation$217.90M$195.50M$194.30M$173.10M$134.20M
Share buybacks$167.70M$300.00M$0$0—

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.